First Clinical Results for PSMA-Targeted α-Therapy Using 225Ac-PSMA-I&T in Advanced-mCRPC Patients
Open accessThe DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Abstract
Treatment of advanced metastatic castration-resistant prostate cancer after failure of approved therapy options remains challenging. Prostate-specific membrane antigen (PSMA)–targeting β- and α-emitters have been introduced, with promising response rates. Here, we present the first—to our knowledge—clinical data for PSMA-targeted α-therapy (TAT) using 225Ac-PSMA imaging and therapy (I&T). Methods: Fourteen patients receiving 225Ac-PSMA-I&T were included in this retrospective analysis. Eleven of the 14 had prior second-line antiandrogen treatment with abiraterone or enzalutamide, prior chemotherapy, and prior 177Lu-PSMA treatment. Patients were treated at bimonthly intervals until progression or intolerable side effects. Prostate-specific antigen (PSA) was measured for response assessment. Hematologic and nonhematologic side effects were recorded according to the Common Terminology Criteria for Adverse Events, version 5.0. Results: Thirty-four cycles of 225Ac-PSMA-I&T were applied (median dose, 7.8 MBq; range, 6.0–8.5), with 1 cycle in 3 patients, 2 cycles in 7 patients, 4 cycles in 3 patients, and 5 cycles in 1 patient. No acute toxicity was observed during hospitalization. Baseline PSA was 112 ng/mL (range, 20.5–818 ng/mL). The best PSA response after TAT (a PSA decline ≥ 50%) was observed in 7 patients, and a PSA decline of any amount was observed in 11 patients. Three patients had no PSA decline at any time. A subgroup analysis of 11 patients with prior 177Lu-PSMA treatment showed any PSA decline in 8 patients and a decline of at least 50% in 5 patients. After TAT, grade 3 anemia was observed in 3 of the 14 patients, with 2 of them presenting with grade 2 anemia already at baseline. Grade 3 leukopenia was observed in 1 patient. Eight patients with preexisting xerostomia after 177Lu-PSMA showed no worsening after TAT. Newly diagnosed grade 1 or 2 xerostomia after TAT was observed in 5 patients. One patient reported no xerostomia at all. Conclusion: Our first clinical data for TAT using 225Ac-PSMA-I&T showed a promising antitumor effect in advanced metastatic castration-resistant prostate cancer. These results are highly comparable to data on 225Ac-PSMA-617 TAT.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hofman, M. S., Violet, J., Hicks, R. J., Ferdinandus, J., Thang, S. P., Akhurst, T., Iravani, A., Kong, G., Ravi Kumar, A., Murphy, D. G., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30198-0 · Cited by 1,174 · cited 1×
“The efficacy of (177)Lu-PSMA RLT was confirmed in the phase 2 Lu-PSMA trial, with a prostate-specific antigen (PSA) decline of any amount observed in almost all patients (29/30, 97%) (5).”
BackgroundKratochwil, C., Bruchertseifer, F., Giesel, F. L., Weis, M., Verburg, F. A., Mottaghy, F., Kopka, K., Apostolidis, C., Haberkorn, U., & Morgenstern, A. (2016) · Journal of Nuclear Medicine · doi:10.2967/jnumed.116.178673 · Cited by 1,100 · cited 1×
“Targeted alpha therapy (TAT) using 225Ac-PSMA-617 has been introduced with substantial therapeutic efficacy and has the potential to overcome resistance to βemitter therapy (6, 7).”
BackgroundRahbar, K., Ahmadzadehfar, H., Kratochwil, C., Haberkorn, U., Schäfers, M., Essler, M., Baum, R. P., Kulkarni, H. R., Schmidt, M., Drzezga, A., et al. (2017) · Journal of Nuclear Medicine · doi:10.2967/jnumed.116.183194 · Cited by 832 · cited 1×
“In the largest retrospective cohort with overall 145 patients, 40% did not show any response at all (4).”
BackgroundSelf-citationWeineisen, M., Schottelius, M., Simecek, J., Baum, R. P., Yildiz, A., Beykan, S., Kulkarni, H. R., Lassmann, M., Klette, I., Eiber, M., et al. (2015) · Journal of Nuclear Medicine · doi:10.2967/jnumed.115.158550 · Cited by 532 · cited 1×
“as a theranostic PSMA-targeting small molecule (11,12).”
Baum, R. P., Kulkarni, H. R., Schuchardt, C., Singh, A., Wirtz, M., Wiessalla, S., Schottelius, M., Mueller, D., Klette, I., & Wester, H.-J. (2016) · Journal of Nuclear Medicine · doi:10.2967/jnumed.115.168443 · Cited by 525 · cited 1×
“First clinical results for 177LuPSMA-I&T were highly comparable to 177Lu-PSMA-617 data (13).”
ResultKratochwil, C., Bruchertseifer, F., Rathke, H., Bronzel, M., Apostolidis, C., Weichert, W., Haberkorn, U., Giesel, F. L., & Morgenstern, A. (2017) · Journal of Nuclear Medicine · doi:10.2967/jnumed.117.191395 · Cited by 505 · cited 4×
“In the last years several groups presented remarkable clinical efficacy of PSMA TAT using 225Ac-PSMA-617 in different settings including chemotherapynaïve, diffuse metastatic and 177Lu-PSMA RLT refractory patients (8, 10, 14, 16, 17).”
BackgroundMethodInfluentialKratochwil, C., Bruchertseifer, F., Rathke, H., Hohenfellner, M., Giesel, F. L., Haberkorn, U., & Morgenstern, A. (2018) · Journal of Nuclear Medicine · doi:10.2967/jnumed.117.203539 · Cited by 421 · cited 2×
“5 on 40 patients treated with 8 MBq (100 kBq/kgBW) every two months have shown highly promising results with PSA decline ≥ 50% in 63% and any PSA response in 87% of patients (8).”
BackgroundMethod225Ac-PSMA-617 in chemotherapy-naive patients with advanced prostate cancer: a pilot study
Sathekge, M., Bruchertseifer, F., Knoesen, O., Reyneke, F., Lawal, I., Lengana, T., Davis, C., Mahapane, J., Corbett, C., Vorster, M., et al. (2019) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-018-4167-0 · Cited by 354 · cited 2×
“Such a protocol was also applied in 17 chemotherapy-naïve mCRPC patients, and an overall PSA decline of at least 50% was observed in 15 patients (88%) while maintaining low toxicity (10).”
BackgroundMethodKhreish, F., Ebert, N., Ries, M., Maus, S., Rosar, F., Bohnenberger, H., Stemler, T., Saar, M., Bartholomä, M., & Ezziddin, S. (2020) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-019-04612-0 · Cited by 215
Targeted radionuclide therapy in combined-modality regimens
Gill, M. R., Falzone, N., Du, Y., & Vallis, K. A. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30379-0 · Cited by 181
Weineisen, M., Simecek, J., Schottelius, M., Schwaiger, M., & Wester, H.-J. (2014) · EJNMMI Research · doi:10.1186/s13550-014-0063-1 · Cited by 179 · cited 2×
“PSMA-I&T was introduced as a PSMA targeting small molecule enabling imaging and therapy of prostate cancer using the same compound (11).”
BackgroundPSMA-Targeted Radiopharmaceuticals for Imaging and Therapy
Wester, H.-J., & Schottelius, M. (2019) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2019.02.008 · Cited by 165 · cited 2×
“PSMA overexpression in PC represents the ideal target for theranostic approaches using radiolabeled ligands for imaging and therapy (3).”
BackgroundMetastatic prostate cancer remains incurable, why?
Dong, L., Zieren, R. C., Xue, W., de Reijke, T. M., & Pienta, K. J. (2019) · Asian Journal of Urology · doi:10.1016/j.ajur.2018.11.005 · Cited by 164 · cited 1×
“4 INTRODUCTION Progression of Prostate Cancer (PC) after salvage therapy and androgen deprivation therapy (ADT) marks the transition to metastatic castration resistant prostate cancer (mCRPC), which describes the incurable and lethal form of advanced PC where treatment remains highly challenging (1).”
Background225Ac-PSMA-617 for Therapy of Prostate Cancer
Kratochwil, C., Haberkorn, U., & Giesel, F. L. (2020) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2020.02.004 · Cited by 136 · cited 2×
“Ac-PSMA TAT over (177)Lu-PSMA RLT in terms of hematologic toxicity (7,21).”
BackgroundMethodTargeted Radionuclide Therapy of Prostate Cancer—From Basic Research to Clinical Perspectives
Czerwińska, M., Bilewicz, A., Kruszewski, M. K., Węgierek-Ciuk, A., & Lankoff, A. (2020) · Molecules · doi:10.3390/molecules25071743 · Cited by 116
Salivary Gland Toxicity of PSMA Radioligand Therapy: Relevance and Preventive Strategies
Langbein, T., Chaussé, G., & Baum, R. P. (2018) · Journal of Nuclear Medicine · doi:10.2967/jnumed.118.214379 · Cited by 107 · cited 9×
“Up to now all clinical data on PSMA TAT is available only for 225Ac-PSMA-617.”
BackgroundInfluentialRathke, H. G., Kratochwil, C., Hohenberger, R., Giesel, F. L., Bruchertseifer, F., Flechsig, P., Morgenstern, A., Hein, M., Plinkert, P. K., Haberkorn, U., et al. (2018) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-018-4135-8 · Cited by 99
Marshall, C. H., & Antonarakis, E. S. (2020) · Cancer Treatment and Research Communications · doi:10.1016/j.ctarc.2020.100164 · Cited by 33 · cited 2×
“Approved therapy options for mCRPC include second generation antiandrogen therapy, taxane based chemotherapy and radium-223 (2).”
Background
Cited by
Overview of the Most Promising Radionuclides for Targeted Alpha Therapy: The “Hopeful Eight”
Eychenne, R., Chérel, M., Haddad, F., Guérard, F., & Gestin, J.-F. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13060906 · Cited by 196
“It has to be mentioned that a similar radioligand, 225Ac-PSMA-I&T, was recently tested in clinical applications in the same model, in patients after 177Lu-PSMA-617 treatment failure [73,74].”
Schuchardt, C., Zhang, J., Kulkarni, H. R., Chen, X., Müller, D., & Baum, R. P. (2022) · Journal of Nuclear Medicine · doi:10.2967/jnumed.121.262713 · Cited by 187
Bismuth-213 for targeted radionuclide therapy: from atom to bedside.
Ahenkorah, S., Cassells, I., Deroose, C. M., Cardinaels, T., Burgoyne, A. R., Bormans, G., Ooms, M., & Cleeren, F. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13050599 · Cited by 120
“Optimal clinical injected activities depend on the vector molecules; for prostate-specific membrane antigen (PSMA) targeting radiopharmaceuticals, this has been determined to be 4-8 MBq of 225Ac [20,21].”
BackgroundHooijman, E. L., Chalashkan, Y., Ling, S. W., Kahyargil, F. F., Segbers, M., Bruchertseifer, F., Morgenstern, A., Seimbille, Y., Koolen, S. L. W., Brabander, T., et al. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13050715 · Cited by 59
Imaging-guided targeted radionuclide tumor therapy: From concept to clinical translation
Sun, J., Huangfu, Z., Yang, J., Wang, G., Hu, K., Gao, M., & Zhong, Z. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2022.114538 · Cited by 57
Metadata
- Authors
- Zacherl, M. J., Gildehaus, F. J., Mittlmeier, L., Böning, G., Gosewisch, A., Wenter, V., Unterrainer, M., Schmidt-Hegemann, N., Belka, C., Kretschmer, A., Casuscelli, J., Stief, C. G., Unterrainer, M., Bartenstein, P., Todica, A., & Ilhan, H.
- Venue
- Journal of Nuclear Medicine
- Publisher
- Society of Nuclear Medicine
- Published
- 2020-10-02
- Volume
- 62
- Issue
- 5
- Pages
- 669-674
- ISSN
- 0161-5505 (ISSN-L)
- 2159-662X
- OpenAlex
- W3089634467
- Cited by
- 189
- References
- 18
- FWCI
- 9.19
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.